ADP Needs a New CFO, Says Research Firm
In rebutting Bill Ackman's call for a new CEO of ADP, Management CV suggests the problem is in the finance chief's office.
Ackman Presses for Strategy Changes at ADP
The activist investor says ADP could more than double its stock price if it cut staff and made better investments in technology.
Bill Ackman, ADP Heading for Proxy Fight?
The activist investor is planning to name a minority slate to the ADP board as he seeks "transformational change" at the company.
Herbalife to Revamp Distributor Compensation
The company will restructure its compensation system to settle FTC charges that it made false promises to distributors about their potential income.
Regulator Bars Valeant Officers From Trading
A Canadian regulator issues a cease trade order after the troubled drug maker announces it would be late filing financial reports.
Railways: Doing the Locomotion
The second golden age of American railroads is drawing to a close. Consolidation may follow.
Activist Investor Can’t Dodge Insider Trading Suit
A judge finds Bill Ackman can be sued for allegedly buying a stake in Allergan based on inside information about a takeover bid by Valeant Pharmaceuticals.
Watchdogs Call for Shorter Window for Activist Disclosures
Groups say loopholes in securities laws allow activist investors to secretly buy large stakes in companies before initiating hostile takeovers.
Ackman’s Allergan Takeover Bid Is Easier Said Than Done
The takeover contest's outcome becomes unclear when we consider the conflict between the hedge fund’s objectives and the Allergan board's fiduciary duty.